161253-87-8 Usage
Uses
Used in Pharmaceutical Industry:
(R)-2-Benzyloxycarbonylamino-3-(2-methyl-1H-indol-3-yl)-propionic acid is used as a key intermediate in the synthesis of various pharmaceuticals for its potential applications in cancer research and the development of novel therapies for neurodegenerative disorders. Its unique structure allows for the exploration of new treatment options and the enhancement of existing ones.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (R)-2-Benzyloxycarbonylamino-3-(2-methyl-1H-indol-3-yl)-propionic acid serves as a valuable tool for studying cellular signaling pathways. Its properties enable researchers to gain insights into the mechanisms of various diseases and to develop targeted therapies that can potentially improve patient outcomes.
Used in Drug Development:
(R)-2-Benzyloxycarbonylamino-3-(2-methyl-1H-indol-3-yl)-propionic acid is utilized in the design and development of new pharmaceuticals targeting specific protein receptors. Its unique structure and properties make it an attractive candidate for creating drugs with high specificity and efficacy, ultimately contributing to the advancement of personalized medicine and precision therapeutics.
Check Digit Verification of cas no
The CAS Registry Mumber 161253-87-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,1,2,5 and 3 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 161253-87:
(8*1)+(7*6)+(6*1)+(5*2)+(4*5)+(3*3)+(2*8)+(1*7)=118
118 % 10 = 8
So 161253-87-8 is a valid CAS Registry Number.
161253-87-8Relevant academic research and scientific papers
Synthesis and structure-activity relationships of 2-substituted D-tryptophan-containing peptidic endothelin receptor antagonists: Importance of the C-2 substituent of the D-tryptophan residue for endothelin A and B receptor subtype selectivity
Fukami, Takehiro,Yamakawa, Takeru,Niiyama, Kenji,Kojima, Hisaki,Amano, Yuuka,Kanda, Fuyuko,Ozaki, Satoshi,Fukuroda, Takahiro,Ihara, Masaki,Yano, Mitsuo,Ishikawa, Kiyofumi
, p. 2313 - 2330 (2007/10/03)
Continuing studies on modifications of potent cyclic pentapeptide endothelin (ET) receptor antagonists, represented by BQ-123, and potent linear tripeptide derivative ET receptor antagonists, represented by BQ-788, are described herein. The introduction o
